Kiromic BioPharma, Inc.
KRBP · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $2,796 | $2,068 | $470 |
| Gross Profit | $0 | -$2,796 | -$2,068 | -$470 |
| % Margin | – | – | – | – |
| R&D Expenses | $6,854 | $9,625 | $13,920 | $11,368 |
| G&A Expenses | $8,853 | $10,314 | $17,194 | $13,938 |
| SG&A Expenses | $8,853 | $7,519 | $17,194 | $13,938 |
| Sales & Mktg Exp. | $0 | -$2,796 | $0 | $0 |
| Other Operating Expenses | $8,067 | $0 | $0 | $53 |
| Operating Expenses | $23,774 | $17,143 | $31,114 | $25,306 |
| Operating Income | -$23,774 | -$19,939 | -$31,114 | -$25,736 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$3,124 | -$1,010 | -$3,617 | $147 |
| Pre-Tax Income | -$26,898 | -$20,949 | -$34,731 | -$25,589 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$26,898 | -$21,294 | -$38,181 | -$25,654 |
| % Margin | – | – | – | – |
| EPS | -1.03 | -21.41 | -70.12 | -67.4 |
| % Growth | 95.2% | 69.5% | -4% | – |
| EPS Diluted | -1.03 | -21.41 | -70.12 | -67.4 |
| Weighted Avg Shares Out | 26,069 | 32,929 | 16,336 | 11,418 |
| Weighted Avg Shares Out Dil | 26,069 | 32,929 | 16,336 | 11,418 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$3,723 | -$1,852 | $167 | $12 |
| Depreciation & Amortization | $6,847 | $2,796 | $2,068 | $470 |
| EBITDA | -$23,774 | -$16,301 | -$32,497 | -$25,107 |
| % Margin | – | – | – | – |